ReviewSeminars in immunopathology2026
The interaction between inflammation and estrogen in adenomyosis : from molecular mechanisms to therapeutic strategies.
Review in Seminars in immunopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Adenomyosis is a common and difficult disease in gynecology. Its main clinical manifestations include uterine hypertrophy, excessive menstruation, pelvic pain and infertility, which have a serious impact on women's health. Seriously affects women's health. At present, the pathogenesis of this disease is not clear; however, the increase in local estrogen and the occurrence of an inflammatory response are widely believed to be closely related to the development of adenomyotic lesions. Although progress has been made in understanding how estrogen and inflammation play their respective roles in adenomyosis, the relationship between estrogen and inflammation and its impact on adenomyosis are not fully understood. In this work, we summarize the effects of estrogen and inflammation on the occurrence and development of adenomyosis, including the involved biological processes and related signal transduction mechanisms, as well as the targeted drugs for clinical treatment, and further summarize the interactions between the two in adenomyosis as well as the available evidence for clinical applications. This review helps to broaden our understanding of the role of the vicious inflammatory‒estrogen cycle in the pathogenesis and pathophysiology of adenomyosis, and it provides new ideas for the treatment of uterine adenomyosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.